Organon & Co.
OGN · NYSE · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2018–FY2025
- History
- 8 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Organon & Co. at a glance
In FY2025, Organon & Co. reported revenue of USD 6,216 mn, EBITDA of USD 1,587 mn, EBITDA margin of 25.5%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 6,403 | 6,216 | |||
| EBITDA | 1,763 | 1,587 | |||
| EBITDA margin | 27.5% | 25.5% | |||
| Free cash flow | 764 | 538 | |||
| ROIC | 20.8% | 6.7% |
The full 8-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas